Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 8/2016

01.08.2016 | Men’s Health (A Dabaja, Section Editor)

Hormone-Based Treatments in Subfertile Males

verfasst von: Darshan P. Patel, Jason C. Chandrapal, James M. Hotaling

Erschienen in: Current Urology Reports | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Subfertility is defined as the condition of being less than normally fertile though still capable of effecting fertilization. When these subfertile couples seek assistance for conception, a thorough evaluation of male endocrine function is often overlooked. Spermatogenesis is a complex process where even subtle alterations in this process can lead to subfertility or infertility. Male endocrine abnormalities may suggest a specific diagnosis contributing to subfertility; however, in many patients, the underlying etiology is still unknown. Optimizing underlying endocrine abnormalities may improve spermatogenesis and fertility. This manuscript reviews reproductive endocrine abnormalities and hormone-based treatments.
Literatur
1.
2.
Hwang K, Walters RC, Lipshultz LI. Contemporary concepts in the evaluation and management of male infertility. Nat Rev Urol. 2011;8(2):86–94.
3.
Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am. 2008;37(1):67–99. viii.CrossRef
4.
Hotaling JM, Patel Z. Male endocrine dysfunction. Urol Clin N Am. 2014;41(1):39–53.CrossRef
5.
Buck C, Balasubramanian R, Crowley WF, Jr. Isolated gonadotropin-releasing hormone (GnRH) deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington; 1993.
6.
Boehm U, Bouloux PM, Dattani MT, de Roux N, Dode C, Dunkel L, et al. Expert consensus document: European consensus statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547–64.
7.
Layman LC, Cohen DP, Xie J, Smith GD. Clinical phenotype and infertility treatment in a male with hypogonadotropic hypogonadism due to mutations Ala129Asp/Arg262Gln of the gonadotropin-releasing hormone receptor. Fertil Steril. 2002;78(6):1317–20.CrossRefPubMed
8.
Trussell JC. Male reproductive endocrinology: when to replace gonadotropins. Semin Reprod Med. 2013;31(4):237–44.CrossRefPubMed
9.
Farhat R, Al-zidjali F, Alzahrani AS. Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism. Pituitary. 2010;13(2):105–10.CrossRefPubMed
10.
Yang L, Zhang SX, Dong Q, Xiong ZB, Li X. Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. (1573–2584 (Electronic)).
11.
Leisegang K, Bouic PJ, Menkveld R, Henkel RR. Obesity is associated with increased seminal insulin and leptin alongside reduced fertility parameters in a controlled male cohort. Reprod Biol Endocrinol. 2014;12(1):34.CrossRefPubMedPubMedCentral
12.
Eisenberg ML, Kim S, Chen Z, Sundaram R, Schisterman EF, Buck Louis GM. The relationship between male BMI and waist circumference on semen quality: data from the LIFE study. Hum Reprod. 2014;29(2):193–200.CrossRefPubMed
13.
Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril. 2010;93(7):2222–31.CrossRefPubMed
14.
Hammoud AO, Gibson M, Peterson CM, Meikle AW, Carrell DT. Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril. 2008;90(4):897–904.CrossRefPubMed
15.
Katib A. Mechanisms linking obesity to male infertility. Cent European J Urol. 2015;68(1):79–85.
16.
Stokes VJ, Anderson RA, George JT. How does obesity affect fertility in men—and what are the treatment options? Clin Endocrinol. 2015;82(5):633–8.CrossRef
17.
Fejes I, Koloszar S, Zavaczki Z, Daru J, Szollosi J, Pal A. Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl. 2006;52(2):97–102.CrossRefPubMed
18.
Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2015;104(5):1116–26.CrossRef
19.
Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48–51.CrossRefPubMed
20.
Stephens SM, Polotsky AJ. Big enough for an aromatase inhibitor? How adiposity affects male fertility. Semin Reprod Med. 2013;31(4):251–7.CrossRefPubMed
21.
Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011;95(2):809–11.CrossRefPubMed
22.
Hammoud A, Carrell DT, Meikle AW, Xin Y, Hunt SC, Adams TD, et al. An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men. Fertil Steril. 2010;94(5):1734–8.CrossRefPubMed
23.
Su MT, Chen CH, Kuo PH, Hsu CC, Lee IW, Pan HA, et al. Polymorphisms of estrogen-related genes jointly confer susceptibility to human spermatogenic defect. Fertil Steril. 2010;93(1):141–9.CrossRefPubMed
24.
Clyde HR, Walsh PC, English RW. Elevated plasma testosterone and gonadotropin levels in infertile males with hyperthyroidism. Fertil Steril. 1976;27(6):662–6.CrossRefPubMed
25.
Krassas GE, Pontikides N. Male reproductive function in relation with thyroid alterations. Best Pract Res Clin Endocrinol Metab. 2004;18(2):183–95.CrossRefPubMed
26.
Nikoobakht MR, Aloosh M, Nikoobakht N, Mehrsay AR, Biniaz F, Karjalian MA. The role of hypothyroidism in male infertility and erectile dysfunction. Urol J. 2012;9(1):405–9.PubMed
27.
Rajender S, Monica MG, Walter L, Agarwal A. Thyroid, spermatogenesis, and male infertility. Front Biosci (Elite Ed). 2011;3:843–55.
28.
Trummer H, Ramschak-Schwarzer S, Haas J, Habermann H, Pummer K, Leb G. Thyroid hormones and thyroid antibodies in infertile males. Fertil Steril. 2001;76(2):254–7.CrossRefPubMed
29.
Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2009;94(5):1665–70.CrossRefPubMed
30.
Nimkarn S, Gangishetti PK, Yau M, New MI. 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington; 1993.
31.
Reichman DE, White PC, New MI, Rosenwaks Z. Fertility in patients with congenital adrenal hyperplasia. Fertil Steril. 2014;101(2):301–9.CrossRefPubMed
32.
Rohayem J, Tuttelmann F, Mallidis C, Nieschlag E, Kliesch S, Zitzmann M. Restoration of fertility by gonadotropin replacement in a man with hypogonadotropic azoospermia and testicular adrenal rest tumors due to untreated simple virilizing congenital adrenal hyperplasia. Eur J Endocrinol Eur Fed Endocr Soc. 2014;170(4):K11–7.CrossRef
33.
Devoto CE, Madariaga AM, Fernandez W. Congenital adrenal hyperplasia causing male infertility. Report of one case. Rev Med Chil. 2011;139(8):1060–5.CrossRef
34.
Samplaski MK, Loai Y, Wong K, Lo KC, Grober ED, Jarvi KA. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertil Steril. 2014;101(1):64–9.CrossRefPubMed
35.
Kamischke A, Ploger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol. 2000;53(1):43–52.CrossRef
36.
Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab. 1993;77(2):427–32.PubMed
37.
Anderson RA, Wallace AM, Kicman AT, Wu FC. Comparison between testosterone oenanthate-induced azoospermia and oligozoospermia in a male contraceptive study. IV. Suppression of endogenous testicular and adrenal androgens. Hum Reprod. 1997;12(8):1657–62.CrossRefPubMed
38.
Anderson RA, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab. 1996;81(3):896–901.PubMed
39.
Roth MY, Ilani N, Wang C, Page ST, Bremner WJ, Swerdloff RS, et al. Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone ((R)) gels. Andrology. 2013;1(6):899–905.CrossRefPubMedPubMedCentral
40.
Liu PY, Swerdloff RS, Anawalt BD, Anderson RA, Bremner WJ, Elliesen J, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab. 2008;93(5):1774–83.CrossRefPubMed
41.
Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412–20.CrossRefPubMed
42.
Ruhayel Y, Lundin K, Giwercman Y, Hallden C, Willen M, Giwercman A. Androgen receptor gene GGN and CAG polymorphisms among severely oligozoospermic and azoospermic Swedish men. Hum Reprod. 2004;19(9):2076–83.CrossRefPubMed
43.
Martinez-Garza SG, Gallegos-Rivas MC, Vargas-Maciel M, Rubio-Rubio JM, de Los Monteros-Rodriguez ME, Gonzalez-Ortega C, et al. Genetic screening in infertile Mexican men: chromosomal abnormalities, Y chromosome deletions, and androgen receptor CAG repeat length. J Androl. 2008;29(6):654–60.CrossRefPubMed
44.
Sasagawa I, Suzuki Y, Ashida J, Nakada T, Muroya K, Ogata T. CAG repeat length analysis and mutation screening of the androgen receptor gene in Japanese men with idiopathic azoospermia. J Androl. 2001;22(5):804–8.PubMed
45.
Wallerand H, Remy-Martin A, Chabannes E, Bermont L, Adessi GL, Bittard H. Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility. Fertil Steril. 2001;76(4):769–74.CrossRefPubMed
46.
Ferlin A, Vinanzi C, Garolla A, Selice R, Zuccarello D, Cazzadore C, et al. Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. Clin Endocrinol. 2006;65(5):606–10.CrossRef
47.
Sussman EM, Chudnovsky A, Niederberger CS. Hormonal evaluation of the infertile male: has it evolved? Urol Clin N Am. 2008;35(2):147–55. vii.CrossRef
48.
Hill CM, Anway MD, Zirkin BR, Brown TR. Intratesticular androgen levels, androgen receptor localization, and androgen receptor expression in adult rat Sertoli cells. Biol Reprod. 2004;71(4):1348–58.CrossRefPubMed
49.
Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril. 2010;93(7):2232–5.CrossRefPubMed
50.
A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization. Int J Androl. 1992;15(4):299–307.
51.
Weeg N, Shalom-Paz E, Wiser A. Age and infertility: the clinical point of view. Minerva Ginecol. 2012;64(6):477–83.PubMed
52.
Hussein A, Ozgok Y, Ross L, Niederberger C. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl. 2005;26(6):787–91. discussion 92–3.CrossRefPubMed
53.••
Hussein A, Ozgok Y, Ross L, Rao P, Niederberger C. Optimization of spermatogenesis-regulating hormones in patients with non-obstructive azoospermia and its impact on sperm retrieval: a multicentre study. BJU Int. 2013;111(3 Pt B):E110–4. Prospective study that demonstrated that clomiphene citrate can return sperm in the ejaculate of men with non-obstructive azoospermia. Additionally it can also increase sperm retrieval rates within the same cohort.CrossRefPubMed
54.
Reifsnyder JE, Ramasamy R, Husseini J, Schlegel PN. Role of optimizing testosterone before microdissection testicular sperm extraction in men with nonobstructive azoospermia. J Urol. 2012;188(2):532–6.CrossRefPubMed
55.
Ross LS, Kandel GL, Prinz LM, Auletta F. Clomiphene treatment of the idiopathic hypofertile male: high-dose, alternate-day therapy. Fertil Steril. 1980;33(6):618–23.
56.
Pasqualotto FF, Fonseca GP, Pasqualotto EB. Azoospermia after treatment with clomiphene citrate in patients with oligospermia. Fertil Steril. 2008;90(5):2014.e11–2.
57.
Fitzpatrick SL, Berrodin TJ, Jenkins SF, Sindoni DM, Deecher DC, Frail DE. Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology. 1999;140(9):3928–37.
58.
Fontenot GK, Wiehle RD, Podolski JS. Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice. BJU Int. 2016;117(2):344–50.
59.•
Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102:720–7. 1556–5653 (Electronic). Phase II clinical trial, for FDA approval, of the active stereoisomer of clomiphene citrate, enclomiphene.CrossRefPubMed
60.
Boonyarangkul A, Vinayanuvattikhun N, Chiamchanya C, Visutakul P. Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. J Med Assoc Thai = Chotmaihet thangphaet. 2015;98(11):1057–63.PubMed
61.
Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013;1(5):749–57.CrossRefPubMed
62.
Moein MR, Tabibnejad N, Ghasemzadeh J. Beneficial effect of tamoxifen on sperm recovery in infertile men with nonobstructive azoospermia. Andrologia. 2012;44 Suppl 1:194–8.CrossRefPubMed
63.
Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol. 2002;167(2 Pt 1):624–9.CrossRefPubMed
64.
Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol. 2001;165(3):837–41.CrossRefPubMed
65.
Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl. 1989;10(3):240–7.CrossRefPubMed
66.••
Helo S, Ellen J, Mechlin C, Feustel P, Grossman M, Ditkoff E, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015;12:1761–9. 1743–6109 (Electronic). Double-blind comparison of clomiphene citrate and anastrazole. Clomiphene citrate resulted in higher testosterone, while patients on anastrazole had lower estrogen levels.CrossRefPubMed
67.
Kliesch S, Behre HM, Nieschlag E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. Eur J Endocrinol Eur Fed Endocr Soc. 1994;131(4):347–54.CrossRef
68.
Burgues S, Calderon MD. Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Hum Reprod. 1997;12(5):980–6.CrossRefPubMed
69.
Yang L, Zhang SX, Dong Q, Xiong ZB, Li X. Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. Int Urol Nephrol. 2012;44(2):393–9.CrossRefPubMed
70.
Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100(6):1542–6.CrossRefPubMed
71.
72.
Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, et al. European Association of Urology guidelines on male infertility: the 2012 update. Eur Urol. 2012;62(2):324–32.CrossRefPubMed
73.
O’Brien JH, Lazarou S, Deane L, Jarvi K, Zini A. Erectile dysfunction and andropause symptoms in infertile men. J Urol. 2005;174(5):1932–4. discussion 4.CrossRefPubMed
74.
Sunderam S, Kissin DM, Crawford S, Anderson JE, Folger SG, Jamieson DJ, et al. Assisted reproductive technology surveillance—United States, 2010. Morb Mortal Wkly Rep Surveill Summ. 2013;62(9):1–24.
75.
Wu AK, Odisho AY, Washington 3rd SL, Katz PP, Smith JF. Out-of-pocket fertility patient expense: data from a multicenter prospective infertility cohort. J Urol. 2014;191(2):427–32.CrossRefPubMed
76.
Hakonsen LB, Thulstrup AM, Aggerholm AS, Olsen J, Bonde JP, Andersen CY, et al. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men. Reprod Health. 2011;8:24.
77.
Rubes J, Lowe X, Moore D, 2nd, Perreault S, Slott V, Evenson D, et al. Smoking cigarettes is associated with increased sperm disomy in teenage men. Fertil Steril. 1998;70(4):715–23.
78.
Said TM, Ranga G, Agarwal A. Relationship between semen quality and tobacco chewing in men undergoing infertility evaluation. Fertil Steril. 2005;84(3):649–53.
79.
Muthusami KR, Chinnaswamy P. Effect of chronic alcoholism on male fertility hormones and semen quality. Fertil Steril. 2005;84(4):919–24.
80.
Bhattacharya SM, Ghosh M, Nandi N. Diabetes mellitus and abnormalities in semen analysis. J Obstet Gynaecol Res. 2014;40(1):167–71.
81.
Product information: Clomid: Clomiphene Citrate. Sanofi-Aventis; 2006.
82.
Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012;60(9):1761–7.CrossRefPubMed
83.
Kuijper EA, Lambalk CB, Boomsma DI, van der Sluis S, Blankenstein MA, de Geus EJ, et al. Heritability of reproductive hormones in adult male twins. Hum Reprod. 2007;22(8):2153–9.CrossRefPubMed
84.
Pietilainen KH, Kaprio J, Vaaralahti K, Rissanen A, Raivio T. Circulating anti-Mullerian hormone levels in adult men are under a strong genetic influence. J Clin Endocrinol Metab. 2012;97(1):E161–4.CrossRefPubMed
85.
Grigorova M, Punab M, Zilaitiene B, Erenpreiss J, Ausmees K, Matulevicius V, et al. Genetically determined dosage of follicle-stimulating hormone (FSH) affects male reproductive parameters. J Clin Endocrinol Metab. 2011;96(9):E1534–41.CrossRefPubMedPubMedCentral
86.
Lee IW, Kuo PH, Su MT, Kuan LC, Hsu CC, Kuo PL. Quantitative trait analysis suggests polymorphisms of estrogen-related genes regulate human sperm concentrations and motility. Hum Reprod. 2011;26(6):1585–96.CrossRefPubMed
87.
Ferlin A, Vinanzi C, Selice R, Garolla A, Frigo AC, Foresta C. Toward a pharmacogenetic approach to male infertility: polymorphism of follicle-stimulating hormone beta-subunit promoter. Fertil Steril. 2011;96(6):1344–9.e2.CrossRefPubMed
Metadaten
Titel
Hormone-Based Treatments in Subfertile Males
verfasst von
Darshan P. Patel
Jason C. Chandrapal
James M. Hotaling
Publikationsdatum
01.08.2016
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 8/2016
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-016-0612-4

Weitere Artikel der Ausgabe 8/2016

Current Urology Reports 8/2016 Zur Ausgabe

Lower Urinary Tract Symptoms & Voiding Dysfunction (H Goldman and G Badlani, Section Editors)

How to Avoid and Deal with Pelvic Mesh Litigation

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Three-Dimensional Imaging of Urethral Stricture Disease and Urethral Pathology for Operative Planning

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Ablative Therapies for the Treatment of Small Renal Masses: a Review of Different Modalities and Outcomes

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Trends in Simple Prostatectomy for Benign Prostatic Hyperplasia

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

3-D Imaging and Simulation for Nephron Sparing Surgical Training

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise